Wanbury Limited, a leading pharmaceutical company in the global API market and domestic branded formulations, has successfully refinanced its outstanding Non-Convertible Debentures (NCDs), resulting in significant interest cost savings.
Key Highlights of the Refinancing
- Wanbury repurchased its 21% Secured NCDs issued in July 2023, amounting to ₹95 crore, from NEO AIF and associates.
- The company secured a ₹175 crore refinancing package from Emerging India Credit Opportunities Fund II, an associate of Investec Capital Services (India) Pvt. Ltd.
- The new facility carries a lower interest rate of 12.5% p.a., significantly reducing Wanbury’s financial burden.
- Of the total refinancing amount, ₹150 crore will be used to repay existing debts, and the balance will support working capital and capital expenditure (capex) for business growth.
- The loan has a five-year repayment period with an average maturity of 3.25 years and includes a nine-month moratorium.
Company’s Vision and Future Growth
Mohan Rayana, Whole-Time Director of Wanbury Ltd., emphasized that the refinancing move highlights the company’s commitment to financial stability and optimizing shareholder returns. He credited Wanbury’s consistent revenue performance and strategic outlook for securing favorable refinancing terms.
About Wanbury Limited
Established in 1988, Wanbury is listed on NSE (Code: WANBURY) and BSE (Code: 524212). The company exports APIs to over 50 countries and operates two USFDA & EUGMP-approved facilities in Andhra Pradesh and Maharashtra. It has a strong formulations portfolio spanning gynaecology, orthopaedics, nutraceuticals, gastrointestinal, anti-inflammatory, and analgesics.
With this refinancing, Wanbury aims to strengthen its growth trajectory, optimize capital structure, and expand its pharmaceutical footprint globally.
